MedTrace Logo

Open Label, Dose Escalation Phase I Study of AZD2281

NCT00572364 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2009-08-20

No results posted yet for this study

Summary

The purpose of the study is to assess the safety and tolerability of AZD2281 following single and multiple oral doses in patients in Japan with advanced solid malignancies

Conditions

  • Advanced Solid Malignancies

Interventions

DRUG

KU-0059436 (AZD2281)(PARP inhibitor)

oral

Sponsors & Collaborators

Principal Investigators

  • James Carmichael · KuDOS/AstraZeneca

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2009-03-31
Completion
2009-06-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00572364 on ClinicalTrials.gov